Hospital and Community Acquired Bacterial Infections Pushing Growth of Anti-Bacterial Drugs Market

This report covers the market for major anti-bacterial drugs marketed today along with a pipeline analysis and takes the reader through 22 major drugs expected to be seen in the period between 2013 and 2019. The report analyzes marketed and approved drugs such as Cubicin, Teflaro/Zinforo, Dificid, Dalvance, Orbactiv, Sivextro, Zerbaxa, Avycaz, Zyvox, Avelox, Augmentin, Zosyn/Tazocin, Invanz and Tygacil. Along with this, it also reports analysis for other expected candidates that include Surotomycin, Solithromycin, Delafloxacin, Plazomycin, Taksta, Cadazolid, Carbavance and Eravacycline. The antibacterial segment includes few of the oldest classes of drugs that have enriched the industry over past several decades. With over 80% of the total market share being held by generics, the major brands hold a small percentage of shares in the market.

Free Sample Report@ http://www.sa-brc.com/Global-Anti-Bacterial-Drugs-Market-Assessment--Forecast-2015-2019/sample2

Oxazolidinones and lipopeptide antibacterials led the way till 2014; however, combination drugs are expected to increase in the coming years significantly competing with novel emerging candidates. Ketolides and macrocyclics candidates such as fidaxomicin and solithromycin are expected to be emerging leaders. Due to the burst in approval of new drugs in the 2013-2015 period, the branded antibacterial market has received a well yearned boost in capital, however it is sad to acknowledge that several large companies are readjusting focus to other areas even after the visibility of avenues to progress and improve the antibiotic field, a stark illustration of this is that of Cubist with a successful antibiotic discovery department. Within months of being acquired, the entire discovery department was made redundant. There is a lot of action and innovation in the antibiotic and antibacterial pipeline with several candidates developed by small innovative companies. Consistent investment in research and development particularly by early-clinical stage companies has been successful in delivering a sustainable pipeline for the market. Several companies such as Cellceutix have expanded into the antibacterial market after discovery of effective lead compounds against highly difficult to treat pan-drug resistant microbes.

SA-BRC analysts monitored trends in the antibacterial drugs market across 6 regions of North America, Europe, Asia-Pacific, Latin America, Middle-East and Africa for 28 major brands and candidate molecules that are segregated as current marketed drugs, pipeline launches and early-stage pipeline candidates that are expected to be available only after 2020. Until recently, the antibacterial pipeline was considered to be completely dry with very few foreseen launches, however 2014-2015 saw five major launches with another 8 expected by the turn of the decade. North America led the way with a market share of 38.9% in 2014. The region remains the largest investor in R&D for pharmaceuticals. Top players in the market are based out of North America and have expanded into central and south Latin American regions. Brazil and Mexico are otherwise the largest target areas within the Americas for big pharma manufacturers. Europe market follows with a share of 24.7% in 2014 but will lose a significant portion of its share to Asia-Pacific.

Click For Full Report@ http://www.sa-brc.com/report/Global-Anti-Bacterial-Drugs-Market-Assessment--Forecast-2015-2019/2

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
10685-B Hazelhurst Drive,
Suite 17411
Houston, Texas 77043,
United States
Phone: +1(832)-426-3701
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.